Bumetanide

Uses

How it works

Dosage & preparation

Risks & contraindications

Comparisons

Evidence quality

Highlighted claims

• The bumetanide target dose in the trial is 0.02 mg/kg twice daily, administered orally morning and evening, with a half-dose titration period in the first week. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial
• Bumetanide is a known diuretic and high-affinity antagonist of the NKCC1 cotransporter. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial
• Hypokalaemia is the most frequently observed adverse effect in bumetanide-treated patients. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial
• Bumetanide has been investigated in numerous neurodevelopmental and neurological conditions involving chloride homeostasis dysregulation, including ASD, Rett syndrome, epilepsy, and neonatal seizures. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial
• Phase III trials of bumetanide 0.5 mg twice daily in ASD failed to demonstrate efficacy. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial
• A meta-analysis of six randomised placebo-controlled trials in 496 children with ASD found bumetanide significantly improved social affect and repetitive behaviours but not sensory symptoms. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial
• Because bumetanide is already FDA-approved, it may allow relatively rapid translation into clinical trials for people with Down syndrome. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial